UPDATED APRIL 7 TO INCLUDE NEW IPR: Hayman Capital’s Kyle Bass and IP Nav’s Erich Spangenberg have targeted a second and third pharmaceutical company at the PTAB, filing inter partes review petitions challenging patents owned by Shire and Jazz
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The model covers court-guided settlements, submissions-led determination of infringement and validity issues, and provides leeway for the court to determine a FRAND rate during negotiations